Skip to main content

Advertisement

Log in

Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment

  • Original Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Background/aim

To evaluate the efficacy and safety of ledipasvir and sofosbuvir therapy for genotype 1b in chronic hepatitis C patients with chronic kidney disease (CKD) stage 3.

Methods

In a multicenter collaborative retrospective study, 706 patients who have received ledipasvir which is NS5A inhibitor, and sofosbuvir 400 mg which is NS5B nucleoside polymerase inhibitor daily for 12 weeks between September 2015 and January 2017 were subjected to this analysis. Virologic response and adverse events in patients with CKD stage 3 were compared with those in patients with CKD stages 1 and 2.

Results

The rates of sustained virologic response (SVR) were 97.0% in patients with CKD stage 1, 97.1% in patients with CKD stage 2, and 94.7% in patients with CKD stage 3, respectively. There were no significant differences in the SVR rates between CKD stages 1 and 2, and CKD stage 1 and stage 3. The incidence of adverse events over than grade 2 was 0% in patients with CKD stage 1, 0.5% in patients with CKD stage 2, and 3.0% in patients with CKD stage 3, respectively. For treatment and follow-up period, eGFR levels in the patients with CKD stage 3 were not worsened compared to those at baseline.

Conclusion

This study suggested that the virologic response of ledipasvir and sofosbuvir in patients with CKD stage 3 was not inferior to those with CKD stages 1 and 2. In addition, administration of ledipasvir and sofosbuvir did not affect eGFR levels in the patients with CKD stage 3.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083–2091

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Mizokami M, Dvory-Sobol H, Izumi N, et al. Resistance analyses of Japanese hepatitis c-infected patients receiving sofosbuvir or ledipasvir/sofosbuvir containing regimens in phase 3 studies. J Viral Hepat 2016;23(10):780–788

    Article  CAS  PubMed  Google Scholar 

  3. Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62(4):1037–1046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kumada H, Suzuki Y, Karino Y, et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J Gastroenterol 2017;52(4):520–533

    Article  CAS  PubMed  Google Scholar 

  5. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370(16):1483–1493

    Article  CAS  PubMed  Google Scholar 

  6. Su F, Beste LA, Green PK, Berry K, Ioannou GN. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients. Eur J Gastroenterol Hepatol 2017;29(6):686–693

    Article  CAS  PubMed  Google Scholar 

  7. Okubo T, Atsukawa M, Tsubota A, et al. Association between vitamin D deficiency and pre-existing resistance-associated hepatitis C virus NS5A variants. Hepatol Res 2017;47(7):641–649

    Article  CAS  PubMed  Google Scholar 

  8. Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007;71(2):159–166

    Article  CAS  PubMed  Google Scholar 

  9. Tsui JI, Vittinghoff E, Shlipak MG, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007;167(12):1271–1276

    Article  PubMed  Google Scholar 

  10. Tsuge M, Hiramatsu A, Shinohara F, et al. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: a case report. Hepatol Res 2016;46(9):944–948

    Article  PubMed  Google Scholar 

  11. Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015;64(3):495–503

    Article  CAS  PubMed  Google Scholar 

  12. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013;3(Suppl):1–150

  13. Fabrizi F, Dixit V, Messa P, Martin P. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies. J Viral Hepat 2014;21(10):681–689

    Article  CAS  PubMed  Google Scholar 

  14. Karino T, Ozeki I, Hige S, et al. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat 2014;21(5):341–347

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kondo C, Atsukawa M, Tsubota A, et al. Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. Hepatol Res 2017. https://doi.org/10.1111/hepr.12879 (epub 2017 Apr 12).

    Google Scholar 

  16. Atsukawa M, Tsubota A, Koushima Y, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatol Res 2017. https://doi.org/10.1111/hepr.12910 (epub ahead of print).

    Google Scholar 

  17. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537–1545

    Article  CAS  PubMed  Google Scholar 

  18. Iio E, Shimada N, Takaguchi K, et al. Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy. Hepatol Res 2017;47:1308–1316

    Article  CAS  PubMed  Google Scholar 

  19. Asahina Y, Izumi N, Hiromitsu K, et al. JSH Guidelines for the management of hepatitis C virus infection: a 2016 update for genotype 1 and 2. Hepatol Res 2016;46(2):129–165

    Article  PubMed  Google Scholar 

  20. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Collaborators developing the Japanese equation for estimated GFR. Am J Kidney Dis 2009;53(6):982–992

    Article  CAS  PubMed  Google Scholar 

  21. Common Terminology criteria for Adverse Events, version 4.0 https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Updated 14 June 2010. Accessed 14 Nov 2017

  22. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976;31(2):155–163

    Article  CAS  PubMed  Google Scholar 

  23. SOVALDI® (sofosbuvir) tablets, for oral use. 2015. Gilead Sciences, Inc. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf. Accessed 14 November 2017

  24. Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 2016;36(6):807–816

    Article  CAS  PubMed  Google Scholar 

  25. Singh T, Guirguis J, Anthony S, Rivas J, Hanouneh IA, Alkhouri N. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series. Liver Int 2016;36(6):802–806. https://doi.org/10.1111/liv.13078 Epub 2016 Feb 22

    Article  CAS  PubMed  Google Scholar 

  26. Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR < 30 ml/min. Liver Int 2016;36(6):798–801

    Article  CAS  PubMed  Google Scholar 

  27. Desnoyer A, Pospai D, Lê MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 2016;65(1):40–47

    Article  CAS  PubMed  Google Scholar 

  28. HCV Guidance: recommendations for testing, managing, and treating hepatitis C. AASLD and IDSA. http://www.hcvguidelines.org. Updated 21 September 2017. Accessed 14 Nov 2017

  29. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017;66(1):153–194

    Article  Google Scholar 

Download references

Funding

This study has no funding sources, grants, or other types of financial support to disclose.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Masanori Atsukawa.

Ethics declarations

All authors are in compliance with ethical standards for this study.

Conflict of interest

Tomomi Okubo, Masanori Atsukawa, Akihito Tsubota, Hidenori Toyoda, Noritomo Shimada, Hiroshi Abe, Keizo Kato, Korenobu Hayama, Taeang Arai, Ai Nakagawa-Iwashita, Norio Itokawa, Chisa Kondo, Chiaki Kawamoto, Etsuko Iio, Yasuhito Tanaka, Takashi Kumada, and Katsuhiko Iwakiri have no conflicts of interest to disclose.

Ethical approval

This study was designed according to the ethical guidelines of the Helsinki Declaration in 2013.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okubo, T., Atsukawa, M., Tsubota, A. et al. Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. Hepatol Int 12, 133–142 (2018). https://doi.org/10.1007/s12072-018-9859-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-018-9859-9

Keywords

Navigation